What’s Coming Next in Transformative Innovation?
Vol 25 No 4 (2020), Commentary
Vol 25 No 4 (2020)

What’s Coming Next in Transformative Innovation? Announcing “The Annual JCB Top 50 Organizations for Transformative Innovation in Biopharma, Med Tech and Digital Health”

Commentary
https://doi.org/10.5912/jcb949
Published December 11, 2020
Arthur A Boni

Abstract

The idea in short. Contiguous with the publication of this special edition focused on the “Promises and Challenges of Transformative Innovation”, it is appropriate that we announce the creation of a new set of annual awards for our industry.  Therefore, in this short article we announce a new set of annual awards honoring excellence in transformative innovation – the JCB Top 50 Innovators!

https://doi.org/10.5912/jcb949
Requires Subscription or Fee PDF

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.